IPSEN (OTCMKTS:IPSEY) Stock Price Passes Above Two Hundred Day Moving Average - Here's What Happened

Key Points

• IPSEN's stock has crossed above its 200-day moving average for the first time, reaching a high of $34.07 during trading.
• The company's current 50-day moving average stands at $32.90, indicating an upward trend in its stock performance.
• IPSEN is a biopharmaceutical company with a diverse product pipeline, including drugs in oncology, neuroscience, and treatments for rare diseases.

IPSEN (OTCMKTS:IPSEY - ) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $30.41 and traded as high as $34.07. IPSEN shares last traded at $34.07, with a volume of 616 shares traded.

IPSEN Trading Up 0.6%

The firm has a fifty day moving average price of $32.90 and a 200-day moving average price of $30.41.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.